American Journal of Gastroenterology 110 ():p S314-S315, October 2015
The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial
However, as shown in our case study, a fixed dosage regimen might not lead to adequate fluconazole exposure in every patient and a personalized dosing regimen might be useful in the achievement of adequate fluconazole Fluconazole (floo kon' a zole) is a fungicidal agent which inhibits lanasterol-14-α-demethylase, the enzyme responsible for ergosterol synthesis
Treatment guidelines for coccidioidomycosis recommend fluconazole therapy and severe or disseminated infections can require lifelong treatment
Case summary: A patient with hepatitis experienced worsening of her liver function when treated with fluconazole for a Candida infection in her urine
Vaginal candidiasis: 150 mg single dose
Fluconazole is a potent inhibitor of the cytochrome P450 3A4 isoenzyme system
Terbinafine should be stopped immediately if LFTs are deranged
2 • Eplerenone labeling: check potassium and renal function three to seven days after starting a moderate CYP3A4 inhibitor (e
Though well tolerated, you should also monitor for a few adverse drug reactions such as elevated LFTs, reversible alopecia and QT prolongation
Caution must be exercised in the following settings: In a retrospective analysis of 134 children prescribed terbinafine (average treatment course 8
All abnormal laboratory results were mild and resolved Fluconazole is a potent inhibitor of the cytochrome P450 3A4 isoenzyme system
Antifungal drugs can be classified as polyenes, antimetabolite—flucytosine (5-FC), azoles, echinocandins, the Voriconazole (vor" i kon' a zole) is a synthetic triazole and a derivative of fluconazole, which is believed to act through inhibition of the fungal 14α-ergosterol demethylase that is responsible for converting lanosterol to ergosterol, which blocks cell membrane synthesis
Medicines Supply Tool
Recent findings Pharmacokinetic 3-6 mg/kg, dose to be given on first day, then 3 mg/kg every 48 hours
g Fluconazole
Check LFT's before starting itraconazole or posaconazole and then monthly dur-ing treatment 2
Rifampin is associated with transient and asymptomatic elevations in serum aminotransferase and bilirubin levels and is a well known cause of clinically apparent, acute liver disease that can be severe and Griseofulvin is FDA approved for and the drug of choice in tinea capitis
The primary objective was to evaluate the number of patients meeting DILIN criteria when receiving fluconazole adverse drug reactions reporting/monitoring, critical care, medication safety, fluconazole Monitoring Adverse Reactions: Headache, reversible hair loss, anorexia, elevated LFTs, prolonged QTc Labs/Tests: AST/ALT at baseline and every 1-2 weeks after, baseline ECG, renal function Drug interactions: As a CYP-enzyme inhibitor, fluconazole has significant drug interactions including oral Avoid concomitant administration of voriconazole and fluconazole
and Cryptococcus) and as an alternative treatment for dermatophyte infections not involving the scalp or nails
The estimated point prevalence of onychomycosis in North America is up to 13
This study uses a large database of adverse events reported to the FDA to evaluate the risk of drug-induced liver injury (DILI) from different antifungal classes and agents
Some patient populations that frequently use itraconazole prophylaxis are patients with HIV, those receiving chemotherapy, or people who have had an organ transplant Discussion
[] In vivo rat studies show that fluconazole is associated with hepatocyte degeneration at Authoring team
50 mL per second per m 2 ]) Low body Users of fluconazole and ketoconazole with chronic liver disease had higher rates of liver aminotransferase levels >200 U/L than those without underlying liver disease (P value interaction <
12 days
Fluconazole has been the preferred treatment for esophageal candidiasis in HIV positive patients, Mean levels of liver function tests were similar between the groups at the EOT where only one patient from each group had transaminase levels 10
We aimed to approximate the risk of clinical acute liver injury among users of oral antifungals in the general population
Frequent monitoring for adverse events is Liver function tests
Outcome and Management
• Treatment: > 1,000 ng/mL: Routine monitoring recommended in all patients
Liver function evaluation before treatment and periodic monitoring every three to six weeks after commencement of treatment is suggested
Fluconazole loading dose: 200 - 400 mg PO OD day 1 and then subsequent dose: 100 mg to 200 mg PO OD
Oral antifungal drugs currently in use include itraconazole, fluconazole, ketoconazole and terbinafine
Background: Fluconazole is a commonly prescribed first-generation triazole antifungal
Have I got the right topic? How up-to-date is this topic? Goals and outcome measures
An improved understanding of antifungal pharmacology and antifungal pharmacokinetics–pharmacodynamics has resulted in therapeutic drug monitoring
References 16 9
Overall, fluconazole is well tolerated and requires very little monitoring
acute or recurrent vaginal candidiasis
7% had baseline and monitoring LFT elevations, respectively, and 3
Fluconazole, ketoconazole
14 days except in severely immunocompromised patients); for 14–30 days in other mucosal infections (e
Atorvastatin — advise against concomitant intake with large quantities (more than 1
Monitoring liver function: Perform baseline LFTs in all patients and do not initiate treatment in patients with baseline values of ALT and/or AST >3 X upper limit of normal
It is not registered for nail infections
Patients who develop abnormal liver function tests during fluconazole therapy should be monitored for the development of more severe hepatic injury Fluconazole 150–300 mg once weekly for 12–24 weeks (fingernails) and 24–52 weeks (toenails) Recurrence rate (follow-up 10–13 months) 33
Monitoring for adverse events and toxicity related to voriconazole is recommended; especially, if voriconazole is started within 24 h after the last dose of fluconazole
Check LFT’s before starting itraconazole or posaconazole and then monthly dur-ing treatment 2
Treatment courses of fluconazole are often short, ranging from 1 day to 3 weeks for